LRRK2 phosphorylates moesin at threonine-558: Characterization of how Parkinson's disease mutants affect kinase activity

Biochemical Journal

Volumn 405, Issue 2, 2007, Pages 307-317

  Jaleel, Mahaboobi ^a   Nichols, R Jeremy ^a   Deak, Maria ^a   Campbell, David G ^a   Gillardon, Frank ^b   Knebel, Axel ^c   Alessi, Dario R ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c Kinasource Ltd   (United Kingdom)

Author keywords

Ezrin radixin moesin family of proteins (ERM proteins); Kinase substrate tracking and elucidation screening (KESTREL screening); Leucine rich repeat kinase 2 (LRRK2); Mass spectrometry (MS); Parkinson's disease (PD); Protein kinase

Indexed keywords

CYTOSKELETON; MOESIN; PHYSIOLOGICAL SUBSTRATES; THREONINE;

CELL MEMBRANES; ENZYME ACTIVITY; MASS SPECTROMETRY; MUTAGENESIS; PHOSPHORYLATION; PROTEINS;

GENETIC ENGINEERING;

ARGINYLLEUCYLGLYCYLARGINYLASPARTYLLYSYLTYROSYLLYSYLTHREONYLLEUCYLARGINYLGLUTAMINYLISOLEUCYLARGINYLGLUTAMINE; EZRIN; GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 2; MOESIN; PEPTIDE; RADIXIN; THREONINE; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; CYTOSKELETON PROTEIN; LRRK2 PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTEIN SERINE THREONINE KINASE;

AMINO ACID SEQUENCE; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME ASSAY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME PURIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ASSAY; RAT; ANIMAL; GENETICS; METABOLISM;

RATTUS;

AMINO ACID SEQUENCE; ANIMALS; CYTOSKELETAL PROTEINS; HUMANS; MEMBRANE PROTEINS; MICROFILAMENT PROTEINS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; RATS; THREONINE;

EID: 34447118788     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20070209     Document Type: Article

References (35)

1. Paisan-Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., Simon, J., van der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A. M., Khan, N. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600
2. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607
3. Mata, I. F., Wedemeyer, W. J., Farrer, M. J., Taylor, J. P. and Gallo, K. A. (2006) LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 29, 286-293
4. Taylor, J. P., Mata, I. F. and Farrer, M. J. (2006) LRRK2: a common pathway for parkinsonism, pathogenesis and prevention? Trends Mol. Med. 12, 76-82
5. Farrer, M., Stone, J., Mata, I. F., Lincoln, S., Kachergus, J., Hulihan, M., Strain, K. J. and Maraganore, D. M. (2005) LRRK2 mutations in Parkinson disease. Neurology 65, 738-740
6. Zabetian, C. P., Samii, A., Mosley, A. D., Roberts, J. W., Leis, B. C., Yearout, D., Raskind, W. H. and Griffith, A. (2005) A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65, 741-744
7. Marin, I. (2006) The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol. Biol. Evol. 23, 2423-2433
8. Goldberg, J. M., Bosgraaf, L., Van Haastert, P. J. and Smith, J. L. (2002) Identification of four candidate cGMP targets in Dictyostelium. Proc. Natl. Acad. Sci. U.S.A. 99, 6749-6754
9. Bosgraaf, L., Russcher, H., Smith, J. L., Wessels, D., Soll, D. R. and Van Haastert, P. J. (2002) A novel cGMP signalling pathway mediating myosin phosphorylation and chemotaxis in Dictyostelium. EMBO J. 21, 4560-4570
10. Bosgraaf, L. and Van Haastert, P. J. (2003) Roc, a Ras/GTPase domain in complex proteins. Biochim. Biophys. Acta 1643, 5-10
11. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298, 1912-1934
12. West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L. and Dawson, T. M. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U.S.A. 102, 16842-16847
13. Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J. et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23, 329-341
14. Cohen, P. and Knebel, A. (2006) KESTREL: a powerful method for identifying the physiological substrates of protein kinases. Biochem. J. 393, 1-6
15. Durocher, Y., Perret, S. and Kamen, A. (2002) High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 30, E9
16. Campbell, D. G. and Morrice, N. A. (2002) Identification of protein phosphorylation sites by a combination of mass spectrometry and solid phase Edman sequencing. J. Biomol. Techn. 13, 121-132
17. Troiani, S., Uggeri, M., Moll, J., Isacchi, A., Kalisz, H. M., Rusconi, L. and Valsasina, B. (2005) Searching for biomarkers of Aurora-A kinase activity: identification of in vitro substrates through a modified KESTREL approach. J. Proteome Res. 4, 1296-1303
18. Bretscher, A., Edwards, K. and Fehon, R. G. (2002) ERM proteins and merlin: integrators at the cell cortex. Nat. Rev. Mol. Cell Biol. 3, 586-599
19. Polesello, C. and Payre, F. (2004) Small is beautiful: what flies tell us about ERM protein function in development. Trends Cell Biol. 14, 294-302
20. Gary, R. and Bretscher, A. (1995) Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site. Mol. Biol. Cell 6, 1061-1075
21. Pestonjamasp, K., Amieva, M. R., Strassel, C. P., Nauseef, W. M., Furthmayr, H. and Luna, E. J. (1995) Moesin, ezrin, and p205 are actin-binding proteins associated with neutrophil plasma membranes. Mol. Biol. Cell 6, 247-259
22. Turunen, O., Wahlstrom, T. and Vaheri, A. (1994) Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family. J. Cell Biol. 126, 1445-1453
23. Pearson, M. A., Reczek, D., Bretscher, A. and Karplus, P. A. (2000) Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell 101, 259-270
24. Huang, L., Wong, T. Y., Lin, R. C. and Furthmayr, H. (1999) Replacement of threonine 558, a critical site of phosphorylation of moesin in vivo, with aspartate activates F-actin binding of moesin. Regulation by conformational change. J. Biol. Chem. 274, 12803-12810
25. Nakamura, F., Huang, L., Pestonjamasp, K., Luna, E. J. and Furthmayr, H. (1999) Regulation of F-actin binding to platelet moesin in vitro by both phosphorylation of threonine 558 and polyphosphatidylinositides. Mol. Biol. Cell 10, 2669-2685
26. Matsui, T., Maeda, M., Doi, Y., Yonemura, S., Amano, M., Kaibuchi, K., Tsukita, S. and Tsukita, S. (1998) Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J. Cell Biol. 140, 647-657
27. Oshiro, N., Fukata, Y. and Kaibuchi, K. (1998) Phosphorylation of moesin by rho-associated kinase (Rho-kinase) plays a crucial role in the formation of microvilli-like structures. J. Biol. Chem. 273, 34663-34666
28. Tran Quang, C., Gautreau, A., Arpin, M. and Treisman, R. (2000) Ezrin function is required for ROCK-mediated fibroblast transformation by the Net and Dbl oncogenes. EMBO J. 19, 4565-4576
29. Paglini, G., Kunda, P., Quiroga, S., Kosik, K. and Caceres, A. (1998) Suppression of radixin and moesin alters growth cone morphology, motility, and process formation in primary cultured neurons. J. Cell Biol. 143, 443-455
30. MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K. and Abeliovich, A. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587-593
31. McClatchey, A. I. and Giovannini, M. (2005) Membrane organization and tumorigenesis - the NF2 tumor suppressor, Merlin. Genes Dev. 19, 2265-2277
32. Boudeau, J., Miranda-Saavedra, D., Barton, G. J. and Alessi, D. R. (2006) Emerging roles of pseudokinases. Trends Cell Biol. 16, 443-452
33. West, A. B., Moore, D. J., Choi, C., Andrabi, S. A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K. L., Dawson, V. L. and Dawson, T. M. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16, 223-232
34. Gloeckner, C. J., Kinkl, N., Schumacher, A., Braun, R. J., O'Neill, E., Meitinger, T., Kolch, W., Prokisch, H. and Ueffing, M. (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15, 223-232
35. Farrer, M. J., Stone, J. T., Lin, C. H., Dachsel, J. C., Hulihan, M. M., Haugarvoll, K., Ross, O. A. and Wu, R. M. (2007) Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat. Disord. 13, 89-92